Inspire Medical Systems Inc
NYSE:INSP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
72.08
215.42
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Inspire Medical Systems Inc
Inspire Medical Systems Inc. emerged as a beacon of innovation in the medical technology landscape, carving a niche within the realm of obstructive sleep apnea (OSA) treatment. Founded with a vision to redefine the approach to sleep disorders, the company developed a breakthrough solution—a device that stimulates the hypoglossal nerve to maintain an open airway during sleep. This technology, known as Inspire therapy, represents a significant departure from traditional treatments like the cumbersome and often uncomfortable Continuous Positive Airway Pressure (CPAP) machines. By addressing the root cause of airway obstruction, Inspire provides an effective, less intrusive alternative, enhancing the overall quality of life for patients who struggle with conventional methods.
Inspire Medical Systems makes money by marketing its implantable device primarily through a network of sleep centers and hospitals. The company operates in a business model that combines device sales with a supportive service infrastructure, ensuring that both healthcare providers and patients are well-acquainted with its innovative therapy. The revenue stream is fueled not only by the initial sales of the device but also through ongoing follow-ups and software updates necessary for optimal device functionality. By positioning itself at the intersection of customer care and cutting-edge technology, Inspire captures significant value in the growing OSA market, all while reinforcing its reputation as a leader in innovative medical solutions.
Inspire Medical Systems Inc. emerged as a beacon of innovation in the medical technology landscape, carving a niche within the realm of obstructive sleep apnea (OSA) treatment. Founded with a vision to redefine the approach to sleep disorders, the company developed a breakthrough solution—a device that stimulates the hypoglossal nerve to maintain an open airway during sleep. This technology, known as Inspire therapy, represents a significant departure from traditional treatments like the cumbersome and often uncomfortable Continuous Positive Airway Pressure (CPAP) machines. By addressing the root cause of airway obstruction, Inspire provides an effective, less intrusive alternative, enhancing the overall quality of life for patients who struggle with conventional methods.
Inspire Medical Systems makes money by marketing its implantable device primarily through a network of sleep centers and hospitals. The company operates in a business model that combines device sales with a supportive service infrastructure, ensuring that both healthcare providers and patients are well-acquainted with its innovative therapy. The revenue stream is fueled not only by the initial sales of the device but also through ongoing follow-ups and software updates necessary for optimal device functionality. By positioning itself at the intersection of customer care and cutting-edge technology, Inspire captures significant value in the growing OSA market, all while reinforcing its reputation as a leader in innovative medical solutions.
Revenue Growth: Inspire reported Q3 revenue of $224.5 million, up 10% year-over-year and reaffirmed full-year revenue guidance of $900–910 million (12–13% growth).
EPS Guidance Raised: The company increased its full-year 2025 EPS guidance to $0.90–$1 per share, up from $0.40–$0.50, citing strong operational performance.
Inspire V Transition: Over 75% of centers have transitioned to the Inspire V system, with nearly all top implanting centers now using it; the transition is expected to be mostly complete by year-end.
Marketing & Operating Leverage: Increased investment in direct-to-consumer marketing is driving strong patient flow, while expense discipline and territory consolidation are boosting operating margins.
Reimbursement Tailwinds: CMS finalized an 11% increase in 2026 physician fee schedule and proposed increased hospital reimbursement for Inspire procedures, expected to support future growth.
2026 Early Outlook: Management indicated early expectations for 10–11% revenue growth in 2026, citing some headwinds but strong momentum with Inspire V, with formal guidance to be provided in January.
GLP-1 Impact: Survey data indicates GLP-1 drugs are increasing patient inflow to sleep centers, which is seen as a net positive for Inspire as many new candidates become eligible for therapy.